Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Thorvardur Ragnar Halfdanarson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8460-1257; OpenAlex author ID A5090608376, A5091519870. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 12

  1. Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma. First author DOI 10.1530/erc-24-0142↗
  2. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16101861↗
  3. Bounding box-based 3D AI model for user-guided volumetric segmentation of pancreatic ductal adenocarcinoma on standard-of-care CTs. Co-author DOI 10.1016/j.pan.2023.05.008↗
  4. N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyac002↗
  5. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10991-2↗
  6. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7041↗
  7. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003284↗
  8. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and… Co-author DOI 10.2214/ajr.20.24567↗
  9. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adeno… Co-author DOI 10.1634/theoncologist.2018-0878↗
  10. Nodal counts and lymph node ratio impact survival after distal pancreatectomy for pancreatic adenocarcinoma. Co-author DOI 10.1007/s11605-014-2566-5↗
  11. Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. First author DOI 10.2217/fon.13.277↗
  12. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Co-author DOI 10.1007/s00280-013-2070-8↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Amit Mahipal · 4 shared papers, 2021–2025 · strength 0.62
  2. Mark Joseph Truty · 5 shared papers, 2021–2023 · strength 0.61
  3. Sean Patrick Cleary · 4 shared papers, 2021–2025 · strength 0.57
  4. Robert R. McWilliams · 4 shared papers, 2021–2024 · strength 0.52
  5. Ajit Harishkumar Goenka · 4 shared papers, 2021–2023 · strength 0.49
  6. Steven R. Alberts · 3 shared papers, 2019–2024 · strength 0.44
  7. Wen Wee Ma · 3 shared papers, 2022–2024 · strength 0.41
  8. Ryan Michael Carr · 2 shared papers, 2024–2025 · strength 0.38
  9. Shounak Majumder · 2 shared papers, 2023–2025 · strength 0.36
  10. Christopher Leigh Hallemeier · 3 shared papers, 2021–2022 · strength 0.36
  11. Rondell Patrell Graham · 3 shared papers, 2021–2022 · strength 0.36
  12. Michael L. Kendrick · 3 shared papers, 2021–2022 · strength 0.36
  13. Michael G. Haddock · 2 shared papers, 2022 · strength 0.29
  14. George P. Kim · 2 shared papers, 2019–2022 · strength 0.27
  15. Garima Suman · 2 shared papers, 2021–2023 · strength 0.26
  16. Amro M. Abdelrahman · 2 shared papers, 2022 · strength 0.24
  17. Jennifer A. Yonkus · 2 shared papers, 2022 · strength 0.24
  18. Travis Edward Grotz · 2 shared papers, 2022 · strength 0.24
  19. Roberto Alva‐Ruiz · 2 shared papers, 2022 · strength 0.24
  20. Shruti Chandra · 1 shared paper, 2025 · strength 0.22
  21. Kari G. Rabe · 1 shared paper, 2025 · strength 0.22
  22. Samuel O. Antwi · 1 shared paper, 2025 · strength 0.22
  23. Ann L. Oberg · 1 shared paper, 2025 · strength 0.22
  24. Alexander Revzin · 1 shared paper, 2024 · strength 0.17
  25. Sani Haider Kizilbash · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.